EP2292219
Lækningakerfi til að gefa rívastigmín um húð
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
10.10.2006EP published:
12.6.2013EP application number:
10179085.5
EP translation filed:
25.6.2013Grant published:
15.7.2013EPO information:
European Patent Register
Max expiry date:
9.10.2026Expiry date:
9.10.2018
Title:
Transdermal therapeutic system for the administration of rivastigmine
Timeline
Today
10.10.2006EP application
12.6.2013EP Publication
25.6.2013Translation submitted
15.7.2013Registration published
9.10.2018Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056, Basel, CH
Name:
LTS LOHMANN Therapie-Systeme AGAddress:
Lohmannstrasse 2, 56626, Andernach, DE
Inventor
Name:
Gargiulo, Paul M.Address:
New York, NY, US
Name:
Lane, Roger MichaelAddress:
New York, NY, US
Name:
Platt, BeatrixAddress:
Hausten, DE
Name:
Theobald, FrankAddress:
Bad Breisig, DE
Name:
Wall, BettinaAddress:
Neuwied-Niederbieber, DE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
741511 PDate:
1.12.2005Country:
US
Classification
Categories:
A61K 9/70, A61K 31/27
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 10.9.2013
Expires: 9.10.2014
Payer: Árnason Faktor
Number: 9
Paid: 9.9.2014
Expires: 9.10.2015
Payer: Árnason Faktor
Number: 10
Paid: 10.9.2015
Expires: 9.10.2016
Payer: Árnason Faktor
Number: 11
Paid: 6.9.2016
Expires: 9.10.2017
Payer: Árnason Faktor
Number: 12
Paid: 27.9.2017
Expires: 9.10.2018
Payer: Árnason Faktor